logo
This Weird Pyramid Always Lands on the Same Face, Confirming 40-Year-Old Theory

This Weird Pyramid Always Lands on the Same Face, Confirming 40-Year-Old Theory

Gizmodo05-07-2025
'Bille' is the first-ever monostable tetrahedron, or a pyramid-like shape with four triangular faces that has one stable resting position. What this means is that Bille, no matter how you throw it and how it lands, will flip back on exactly the same side every single time.
In a recent preprint submitted to arXiv, mathematicians revealed the first physical model of Bille, closing a decades-old theory proposed by the renowned British mathematician John Conway. Made of lightweight carbon fiber and dense tungsten carbide, Bille represents an array of ridiculously sophisticated engineering decisions—making this as much a technological achievement as a mathematical one.
It's no surprise, therefore, that its self-righting property additionally hints at some exciting applications for the spaceflight industry—which notably experienced two recent landing mishaps with toppled-over lunar landers.
In his initial conjecture, Conway surmised that a tetrahedron with unevenly distributed weight across its sides would always flip to the same side, although a few years later Conway himself rejected the idea. Some mathematicians still thought there could be something to it, however, namely study co-author Robert Dawson, who almost succeeded in proving Conway right in the 1980s using lead foil and sticks of bamboo.
'But my recollection was that this only almost worked because of angular momentum,' Dawson, now a mathematician at Saint Mary's University in Canada, told Gizmodo. 'In the way that if a car comes across a bump in the road and it's already moving, it'll get over it thanks to angular momentum. But it might have a hard time starting up against that bump.'
Ideally, the monostable tetrahedron shouldn't need another push to flop back on the 'base' side. For a while, it seemed like Conway's theory would end up in a box of really-cool-but-unlikely math ideas—until about three years ago, when mathematician Gábor Domokos and his student, Gergő Almádi at the Budapest University of Technology and Economics, reached out to Dawson. Domokos, a long-time expert on tricky balancing problems in geometry, had already discovered the gömböc, a roundish object that balances only on two points like a roly-poly toy.
While an impressive discovery, the gömböc, with its mostly round, multi-sided design, features relatively easy conditions for self-balancing, Domoko told Gizmodo. The fewer sides a figure has and the smaller the angles are on each side, the harder it is to make that figure monostable, he said.
Picture the common six-sided die. 'If it is a fair die, it will land on each face with equal probability,' Domoko explained. Even if someone cheats and modifies the die by putting some extra weight on a couple of surfaces, the probability will shift slightly, but it should still be possible for the die to stand on all its faces.
In that sense, the tetrahedron, with its pointy corners and tiny acute angles across its four sides, makes it the 'most difficult problem, the highest category' of shapes in terms of monostability—barring some kind of engineering miracle.
Which really happened. After deriving a theoretical model to calculate Bille's dimensions, Almádi, an architecture student, spearheaded the quest to build a structure that, somehow, had one side made from a 'really heavy material, the lighter parts almost air, and an almost empty skeleton,' Domokos said. The team settled on carbon tubes for the skeleton and, for the base, dense tungsten carbide—a metal alloy twice as heavy as steel.
Even after all that, an issue remained: For some reason, Bille kept landing on two different sides, not the one intended side.
'Then we looked at it, and there was a very small glob of glue which was sticking to one end!' Domoko exclaimed. Despite the chief engineer's assurances that it made no difference, Domoko insisted on removing the tiny blob of glue—the density and shape of which were also calculated with ridiculous precision.
And—voilà. Bille made mathematical history.
That said, the engineers played a huge role in making this possible, Domokos clarified. 'They were all part of the creation process—the geometry, engineering, and technological design. They all needed to click. If you take out any of these, it doesn't work.'
To make sure Bille wasn't just a one-time dud, Domokos' team succeeded in making a second model—though this probably isn't something one could easily make at home. 'We wish good luck to anyone doing it,' Domokos joked. 'But somebody doing it now has a huge advantage compared to us, because we didn't know whether it would work.'
Domokos is particularly excited to see what might become of Bille further down the line. One reason Domokos didn't want to stop at merely modeling Bille was because of gömböc, he explained. Like many aesthetically pleasing mathematical breakthroughs, gömböc got a lot of love from artistic communities and natural scientists drawing parallels between turtle shells and gömböc—which Domokos more or less expected.
What he didn't expect was that Novo Nordisk, in collaboration with MIT and Harvard, would take interest in gömböc's design principles for an insulin capsule that self-rights itself once inside a stomach, eliminating the need for needle injections.
'And it sounded so outlandish—like science fiction,' Domokos said. 'Gömböc taught me that physical objects are crucial—there are many bright people out there who are not mathematically minded, but they can look at something and it will reflect in their minds many other things.'
Still, it'll probably be a while—if ever—before Bille ends up in the blueprint for the latest lunar lander, which Domokos knows will be extremely challenging. 'When you develop something, you have to wait and technological innovation will catch up. Sometimes it takes 100 years, sometimes it takes 10 years. Mathematics is always a little bit ahead.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Alien: Earth': New prequel series turns Peter Pan-inspired character into a futurist with deadly ideas
'Alien: Earth': New prequel series turns Peter Pan-inspired character into a futurist with deadly ideas

Yahoo

time17 hours ago

  • Yahoo

'Alien: Earth': New prequel series turns Peter Pan-inspired character into a futurist with deadly ideas

A new 'Alien' prequel series reimagines corporate control and AI fears through a sci-fi lens — with a 'Peter Pan' twist Heading back aboard the Weyland-Yutani spaceship, the world of Alien continues to expand with the prequel series Alien: Earth (premiering at 8:00 p.m. ET on Disney+ in Canada), starring Sydney Chandler, Alex Lawther, Timothy Olyphant, Babou Ceesay and Samuel Blenkin. It's set in the year 2120, two years before the events of Ridley Scott's 1979 film, in a world where five corporations control the globe: Prodigy, Weyland-Yutani, Lynch, Dynamic and Threshold. Boy Kavalier (Blenkin) was a young boy genius when he founded Prodigy. The CEO manufactured a new technological advancement with the creation of hybrids, a type of robot injected with human consciousness. The first hybrid is named Wendy, created amid a race for immortality. Created by Noah Hawley, the Peter Pan element of Alien: Earth is something that he described to reporters as being particularly linked to themes explored in previous Alien projects, but also our real world today. "For me, it started with the fact that I'm raising kids, and I'm raising kids in this world in which the natural world is starting to turn on us and the technology we've created, the jury's out on whether that's going to turn on us," Hawley said. "And when they asked me if I had any ideas for Alien, I thought, well, that's what Alien is about. It's about ... primordial monsters of our past that are trying to kill Sigourney [Weaver]. And then the AI future we realize is also trying to kill her. So humanity is trapped between the AI future and the monsters of the past." "Once I started with this idea of bringing children into this story—the human minds transferred into synthetic bodies—then the Peter Pan analogy came pretty quickly after that." Chandler is tasked with portraying Wendy, with the the actor navigating playing a character that has a "child's consciousness," in an adult form. "Wendy is very much a blank page," Chandler said. "I feel like Noah was able to create a very layered, grounded character." "As far as balancing the two, it really depended on who I was acting with on the day and in what scene. Every actor would bring a different colour to the work, which would kind of give me more information of who I am playing. It was kind of a collaboration of finding Wendy that way. But I would have this image of two magnets kind of pressing up against each other, and you just can't get them to touch as far as the mind, which is known, and this body, which is unknown territory. It's kind of like what's in the middle." But as Hawley highlighted, so much of what informs the Alien franchise is this evaluation of capitalism and corporate control, but the "boy genius" element makes this prequel series very relevant for its 2025 release. "So much of what defines Alien and Aliens is this idea that there's this nameless, faceless Weyland-Yutani corporation and these individuals, the space truckers or the soldiers, ... they're really at the mercy of this nameless, faceless corporation," Hawley said. "In our day and age, our corporations have faces and the faces of these young technocrats, who are celebrity CEO billionaires." "So, if I had done the 1970s version of capitalism, it wouldn't have felt right for the world that we live in today. And so once the Peter Pan analogy emerged in the storytelling, then it became clear that the CEO who invents this hybrid technology should be the Peter Pan character himself in Boy Kavalier. What you see is that it always felt to Yaphet Kotto and Harry Dean Stanton that they were at the whim of this larger corporation. But here, I think we really feel like it really is all about the whim of Boy Kavalier, how he feels from moment to moment. Yeah, let's send these billion-dollar prototypes to a crash site. That sounds like a good idea, right? So we're in a different sort of state where the individual is at the mercy now, not just of this nameless, faceless corporation, but these sort of boy geniuses." Ridley Scott influence: 'I was on the runway, he was on his own runway' Through every Alien-related project, Ridley Scott has been known to connect with the talents helming expansions of the franchise. For Alien: Earth, Hawley connected with the director of the original film, but very much felt like he was able to take his own path. "I started talking to Sir Ridley early on in the process. I had done my due diligence in thinking through an idea that I wanted to explore within the show, but first I wanted to talk to Ridley and see, both his experiences on the first film and then what was in his mind going into Prometheus and Covenant and start to let him in on some of the ideas that that I had for the show," Hawley said. "And every time I spoke to him, he was storyboarding what felt like a different movie. I think in the course of our conversations, it was The Last Duel. It was [House of] Gucci. It was Napoleon. So in the course of making a single season of television, that 87-year-old man made three or four huge films. ...So, we were slacking and he was working. I think my job as a filmmaker is really to make decisions, right? And Ridley's job is the same. I think once he realized that ... he did not have those responsibilities on this show, he wants to move on to the next thing. He's got a real agenda. So, we would speak from time to time, but mostly after I was on the runway, he was on his own runway."

FDA Grants 510(k) Clearance for Sonic Incytes' Velacur ONE™, AI-Guided Point of Care Ultrasound for the Management of Chronic Liver Diseases
FDA Grants 510(k) Clearance for Sonic Incytes' Velacur ONE™, AI-Guided Point of Care Ultrasound for the Management of Chronic Liver Diseases

Yahoo

time20 hours ago

  • Yahoo

FDA Grants 510(k) Clearance for Sonic Incytes' Velacur ONE™, AI-Guided Point of Care Ultrasound for the Management of Chronic Liver Diseases

VANCOUVER, British Columbia, August 12, 2025--(BUSINESS WIRE)--Sonic Incytes Medical Corp, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur ONE™, its point-of-care ultrasound elastography device. Building on the success of its original model, Velacur™, Velacur ONE™ introduces an enhanced interface and features for improved portability and user experience. These improvements enable broader scalability to support Sonic Incytes' accelerated US and global expansion strategy. Velacur ONE™ measures attenuation, VDFF (Velacur Determined-Fat Fraction), and liver stiffness using 3D S-WAVE and aids in the management of chronic liver disease including MASH and MASLD. Velacur ONE™ arrives at a critical time for improved non-invasive testing, following the recent FDA clearance of Rezdiffra—the first therapeutic for Metabolic dysfunction–associated steatohepatitis (MASH), a progressive and often underdiagnosed liver disease. In the U.S. alone, an estimated 100 million adults have Metabolic dysfunction–associated Steatotic Liver Disease (MASLD)1, with 15–20 million of those affected by MASH2. Yet, 90% of MASH cases remain undiagnosed3. If left untreated, worsening MASH increases morbidity and may progress to severe complications, including cirrhosis, liver failure, liver cancer, and liver transplant4,5. MASH remains challenging to diagnose effectively due to the limitations of existing non-invasive methods, especially those available at the point-of-care. With the first therapeutic now available and more in the pipeline, clinicians need improved non-invasive tests to diagnose and monitor MASH at point-of-care6. Current treatment guidelines for MASH recommend imaging-based elastography, such as Velacur™, to assess liver scarring (fibrosis) and fat content (steatosis). While ultrasound elastography is widely used, when it comes to treating patients with MASH, liver stiffness alone cannot be relied on to assess treatment response in the short term7. The best predictor of treatment responses was a decrease in steatosis (identified as ≥30% reduction in MRI-PDFF)8. VDFF, Sonic Incytes' proprietary algorithm that received FDA clearance in 2024, demonstrates a strong correlation (r = 0.85) with MRI-PDFF—the gold standard for liver fat measurement—and achieves an outstanding accuracy (AUC) of 95% of patients with more than 5% MRI-PDFF, defining the presence of hepatic steatosis9. Velacur ONE™ combines this technology with a refined user interface, including B-mode imaging—enabling 3–4x higher reimbursement than non-imaging elastography—and an AI-based organ overlay feature to aid in liver localization, making it the only point-of-care device that estimates both liver stiffness and attenuation that correlates to MRI-PDFF10. "The launch of Velacur ONE™ marks a pivotal milestone for Sonic Incytes as we accelerate our US and global commercial expansion strategy," said Barry Allen, CEO of Sonic Incytes. "This next-generation device enhances clinical utility and operational scalability, positioning us to better support the growing demand for accessible, non-invasive liver diagnostics and treatment, particularly in the management of MASLD and MASH at the point-of-care." About Sonic Incytes Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur™ offers real-time, AI-guided quantification of the key markers for fatty liver disease: liver stiffness, attenuation and VDFF. With real-time results, a low up-front cost and AI guidance, Velacur™ makes liver imaging at the point-of-care affordable and accessible. For more information, visit ________________________________ 1 American Liver Foundation. (2025, June). Nonalcoholic fatty liver disease (NAFLD). American Liver Foundation 2 Le P, Tatar M, Dasarathy S, et al. Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707. doi:10.1001/jamanetworkopen.2024.54707 3 Fishman, J., Kim, Y., Charlton, M.R. et al. Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis. Adv Ther 41, 4172–4190 (2024). 4 Friedman SL. Fat, fibrosis, and the future: navigating the maze of MASLD/MASH. J Clin Invest. 2025 Apr 1;135(7):e186418. doi: 10.1172/JCI186418. PMID: 40166940; PMCID: PMC11957683. 5 Fishman J, Alexander T, Kim Y, Kindt I, Mendez P. A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol. J Comp Eff Res. 2024 Oct;13(10):e240085. doi: 10.57264/cer-2024-0085. Epub 2024 Sep 20. PMID: 39301878; PMCID: PMC11426282. 6 Gbadamosi, S. O., Evans, K. A., Brady, B. L., & Hoovler, A. (2025). Noninvasive tests and diagnostic pathways to MASH diagnosis in the United States: a retrospective observational study. Journal of Medical Economics, 28(1), 314–322. 7 Noureddin, M., Charlton, M. R., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R., Sanyal, A. J., & Rinella, M. E. (2024). Expert panel recommendations: Practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis. Clinical Gastroenterology and Hepatology, 22(12), 2367–2377. 8 Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18. Erratum in: Hepatology. 2025 Apr 1;81(4):E133. 9 Honarvar, M., Lobo, J., Schneider, C., Klein, S., Smith, G. I., Loomba, R., Ramji, A., Hassanein, T., Yoshida, E. M., Pang, E., Curry, M. P., & Afdhal, N. H. (2024). Methods and validation of Velacur determined fat fraction in patients with MASLD. WFUMB Ultrasound Open, 2(2), Article 100061. View source version on Contacts Mediacommunications@ 1-800-881-0096

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store